Revealing tumor immunity after hematopoietic stem cell transplantation

Clinical Cancer Research

Volumn 15, Issue 14, 2009, Pages 4515-4517

  Wu, Catherine J ^a   Ritz, Jerome ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MINOR HISTOCOMPATIBILITY ANTIGEN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; NOTE; PRIORITY JOURNAL; TUMOR IMMUNITY;

ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOCYTES, MONONUCLEAR; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 68049095267     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0873     Document Type: Note

References (12)

1. Nishida T, Hudecek M, Kostic A, et al. Development of tumor-reactive T cells after non myeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia. Clin Can Res 2009;15:4759-4768
2. Wu CJ, Ritz J. Induction of tumor immunity following allogeneic stem cell transplantation. Adv Immunol 2006;90:133-73. PubMed doi:10.1016/S0065- 2776(06)90004-90012 (Pubitemid 43765800)
3. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979;300:1068-1073 PubMed. (Pubitemid 9198740)
4. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus- leukemia reactions after bone marrow transplantation. Blood 1990;75:555-562 PubMed.
5. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-2465 PubMed.
6. Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005;105:1810-1814 PubMed doi:10.1182/blood- 2004-05-1947. (Pubitemid 40223707)
7. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine- based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16:2817-2824 PubMed. (Pubitemid 28363047)
8. Mullally A, Ritz J. Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood 2007;109:1355-62. PubMed doi:10.1182/blood-2006- 06-030858. (Pubitemid 46239565)
9. Randolph SS, Gooley TA, Warren EH, Appelbaum FR, Riddell SR. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood 2004;103:347-352 PubMed doi:10.1182/blood-2003-07-2603.
10. Riddell SR, Berger C, Murata M, Randolph S, Warren EH. The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. Blood Rev 2003;17:153-162 PubMed doi:10.1016/S0268-960X(03)00007-9. (Pubitemid 36876675)
11. Wu CJ, Yang XF, McLaughlin S, et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest 2000;106:705-714 PubMed doi:10.1172/JCI10196. (Pubitemid 30691342)
12. Wu CJ, Biernacki M, Kutok JL, et al. Graft-versus- leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells. Clin Cancer Res 2005;11:4504-4511 PubMed doi:10.1158/1078-0432.CCR-05- 0036. (Pubitemid 40825641)